Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 16/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693589 | 0.91 | TBXA2R (0.45) | TBXA2R | |
| SCHEMBL12693469 | 0.90 | TBXA2R (0.47) | TBXA2RUSP2GAAKMT2A | |
| SCHEMBL693203 | 0.88 | TBXA2R (0.46) | TBXA2RGAA | |
| SCHEMBL2820705 | 0.88 | TBXA2R (0.46) | TBXA2R | |
| SCHEMBL694163 | 0.87 | TBXA2R (0.45) | TBXA2RGAAKMT2A | |
| SCHEMBL12693493 | 0.87 | TBXA2R (0.48) | TBXA2RUSP2GAAKMT2A | |
| SCHEMBL16716753 | 0.87 | TBXA2R (0.44) | TBXA2RUSP2GAAKMT2A | |
| SCHEMBL12693282 | 0.86 | LMNA (0.49) | TBXA2RUSP2GAAKMT2A | |
| SCHEMBL694654 | 0.85 | LMNA (0.52) | TBXA2RGAAKMT2A | |
| SCHEMBL693683 | 0.85 | TBXA2R (0.45) | TBXA2RUSP2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2502921-B1 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658642-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420639-B2 | Arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502921-A1 | Arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123960-A2 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273795-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TBXA2R 2704/4885USP2 1309/4885GAA 2694/4885 |
| US-20130217687-A1 | ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TBXA2R 2704/4885USP2 1309/4885GAA 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.